Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. The company's product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other solid tumors and fibrotic diseases indications, that has completed Phase I clinical trial; and AMP886 for acute myeloid leukemia (AML) and certain solid tumors.It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
| Market Capitalization | $15.5205 million |
| P/E Ratio | 0 |
| P/E Growth Ratio | |
| Book Value | 0.082 |
| Dividend Per Share | 0 |
| Earnings Per Share | -0.03 |
| EBITDA | -6,275.534 |
| Profit Margin | 0 |
| Operating Margin TTM | -5.2845 |
| Return on Assets TTM | -0.182 |
| Return on Equity TTM | -0.3313 |
| Revenue TTM | 1,189.486 |
All numbers are in thousands
| Date | Total Revenue | Cost of Revenue | Gross Profit | Total Operating Expenses |
|---|---|---|---|---|
| 2010-03-31 | ||||
| 2011-03-31 | ||||
| 2012-03-31 | ||||
| 2013-03-31 | 237 | |||
| 2014-03-31 | 167 | 4,088.926 | ||
| 2015-03-31 | 30.309 | 238 | 30.309 | 5,428.553 |
| 2016-03-31 | 2,294.75 | 250.346 | 2,012.969 | 7,312.104 |
| 2017-03-31 | 1,831.29 | 205.466 | 1,592.647 | 8,968.805 |
| 2018-03-31 | 642.84 | 102.693 | 477.597 | 4,967.388 |
| 2019-03-31 | 50.47 | 155 | -104 | 1,940.716 |
| 2020-03-31 | 34.23 | 2,257 | ||
| 2021-03-31 | 1,533.52 | 3,874 | ||
| 2022-03-31 | 1,983.32 | 5,626.999 | ||
| 2023-03-31 | 1,148.43 | 7,475.327 |
All numbers are in thousands
| Date | Cash | Total Assets | Total Liabilities | Short Term Debt | Long Term Debt | Common Stock |
|---|---|---|---|---|---|---|
| 2010-03-31 | 1,437 | 10,616 | 2,883 | 1,786 | 119,221 | |
| 2011-03-31 | 2,821 | 10,647 | 2,411 | 2,123 | 122,660 | |
| 2012-03-31 | 1,476 | 7,262 | 3,223 | 267 | 122,662 | |
| 2013-03-31 | 8,359 | 11,426 | 191 | 116,278 | ||
| 2014-03-31 | 7,941.752 | 10,176.209 | 403.731 | 110,223.013 | ||
| 2015-03-31 | 4,088.896 | 5,318.933 | 452.896 | 110,223.013 | ||
| 2016-03-31 | 3,200.622 | 5,034.636 | 1,031.357 | 114,230.766 | ||
| 2017-03-31 | 5,763.357 | 7,536.829 | 907.873 | 0 | 123,018.641 | |
| 2018-03-31 | 2,229.19 | 2,643.67 | 279.422 | 0 | 123,019.417 | |
| 2019-03-31 | 1,240.909 | 9,191.334 | 526.859 | 10.614 | 130,945.206 | |
| 2020-03-31 | 1,108 | 9,116.385 | 510.62 | 0 | 132,903 | |
| 2021-03-31 | 1,848 | 10,879.089 | 539.13 | 0 | 136,554 | |
| 2022-03-31 | 14,608.581 | 24,483.701 | 2,636.063 | 0 | 2,100.473 | 151,507.741 |
| 2023-03-31 | 9,256.677 | 18,684.335 | 2,848.809 | 2,181.148 | 0 | 151,528.974 |
All numbers are in thousands
| Date | Net Income | Total Cash | Change in Cash | Begin period cash | End period cash | Dividends |
|---|---|---|---|---|---|---|
| 2010-03-31 | ||||||
| 2011-03-31 | ||||||
| 2012-03-31 | ||||||
| 2013-03-31 | 116.933 | |||||
| 2014-03-31 | -4,495.458 | -1,604.621 | 7,824.819 | 116.933 | 7,941.752 | |
| 2015-03-31 | -5,236.578 | -3,977.757 | -3,852.856 | 7,941.752 | 4,088.896 | |
| 2016-03-31 | -4,943.098 | -4,714.319 | -888.274 | 4,088.896 | 3,200.622 | |
| 2017-03-31 | -7,076.319 | -6,162.004 | 2,562.735 | 3,200.622 | 5,763.357 | 0 |
| 2018-03-31 | -4,297.58 | -3,548.804 | -3,534.167 | 5,763.357 | 2,229.19 | |
| 2019-03-31 | -1,869.958 | -987.348 | -988.281 | 2,229.19 | 1,240.909 | |
| 2020-03-31 | -2,219.474 | -2,087.977 | -133 | 1,241 | 1,108 | |
| 2021-03-31 | -2,281.153 | -2,916 | 740 | 1,108 | 1,848 | |
| 2022-03-31 | -3,644.217 | 3.209 | 12,760.173 | 1,848.408 | 14,608.581 | |
| 2023-03-31 | -6,296.283 | -6,296.283 | -5,351.904 | 14,608.581 | 9,256.677 |